.jpg?w=340&itok=uR1ZDlop "EPR in healthcare news."){kind=icon}
Happy Holidays from all of us at ICON. We’re sending every best wish for health, happiness and success in 2026.
In the News
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
What does it really take to conduct a vaccine trial at scale?
Dr Nuala Murphy, President of Clinical Services, talks exclusively to Pharmafield about the Pfizer / BioNTech COVID-19 vaccine trial and the implications this has on the future of drug development.
-
Inside the Pfizer/BioNTech COVID-19 vaccine trial: ‘We knew the world was watching and waiting for results’
An article featuring commentary from Dr. Nuala Murphy on ICON’s learnings from conducting the Pfizer/BioNTech trial.
-
How COVID-19 has changed pharmacovigilance
Dr Andrew Garrett contributes to this article in Pharmafocus: How COVID-19 has changed pharmacovigilance. The article explores how drug safety can be ensured while numerous vaccines and treatments come to market in record time to deal with COVID-19.
-
.jpg?w=545&itok=BtGjil7H "EPR in healthcare news.")
The current and future landscape of HIV treatments and vaccines
Dr. Caroline Forkin discusses the current status of HIV treatments and potential for researchers to develop a vaccine.
-
COVID-19 trial of alternating vaccines begins in the UK
Recruitment has begun in the UK for a world-first study to investigate whether using different COVID-19 vaccines for first and second doses is as effective as using the same type of vaccine for both. ICON’s Dr Garrett provides commentary.
-
No10 launches world's first trial into whether mixing and matching coronavirus vaccines can enhance protection
ICON's Dr. Garrett comments on the UK government's new 'Com-Cov' study of over 800 patients, designed to test mixing doses of the Oxford and Pfizer COVID-19 vaccines, as well as different intervals between doses.
-
Inside a vaccine trial
Dr. Murphy of ICON, provider of clinical services to Pfizer/BioNTech’s COVID vaccine program, discusses what it takes to conduct a vaccine trial of this scale.
-
Moderna is designing a new version of its COVID-19 shot to fight the variant first found in South Africa
ICON’s David Morse, VP, Global Regulatory Affairs Consulting Services talks to Business Insider on regulatory pathways for development of new vaccines and vaccine boosters to address emerging COVID-19 variants.
-
ICON supports Pfizer and BioNTech on the investigational COVID-19 vaccine trial
An article explaining how ICON was involved from the very first steps of the trial supporting Pfizer‘s and BioNTech’s implementation of a strategic plan and framework for the monitoring of the trial.
-
Irish pharma group ICON carried out trial of Pfizer-BioNTech vaccine
The Irish Times discusses how ICON carried out the Pfizer-BioNTech vaccine trials.
